Padcev Padcev

Generic name:

ENFORTUMAB VEDOTIN-EJFV

Company:

ASTELLAS

FDA approval date:

12/18/2019

Specific treatment:

PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate
indicated for the treatment of adult patients with locally advanced or
metastatic urothelial cancer who have previously received a programmed
death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and
a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally
advanced or metastatic setting. 

Mechanism of Action:

Enfortumab vedotin-ejfv is an ADC. The antibody is a human IgG1 directed against Nectin-4, an adhesion
protein located on the surface of cells. The small molecule, MMAE, is a microtubule-disrupting agent, attached
to the antibody via a protease-cleavable linker. Nonclinical data suggest that the anticancer activity of
enfortumab vedotin-ejfv is due to the binding of the ADC to Nectin-4-expressing cells, followed by
internalization of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic cleavage. Release of
MMAE disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic
cell death. 

Dosage Form/Route:

For Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized
powder in a single-dose vial for reconstitution.

Side Effects:

The most common adverse reactions (≥20%) included fatigue, peripheral
neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea,
dry eye, pruritus and dry skin.